UniQure, Syndax, Erasca Drawing Fresh Analyst Interest
Three clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Learn the key factors that contribute to a reliable dividend stock. Make informed investment choices for steady income.
20,247 articlesThree clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Ballard Power is at a pivotal moment as 2025 unfolds. This guide breaks down what to watch in the Q4 transcript, how ...
As Assertio prepares to discuss its Q4 2025 results, investors look for clues about product performance, margins, and...
The Invesco S&P 500 Momentum ETF (SPMO) is again outperforming SPY on a trailing basis while showing resilience durin...
Occidental Petroleum surges in 2026 on debt cleanup after the OxyChem sale, with oil prices supportive but questions ...
Berkshire Hathaway names Greg Abel as CEO, with Buffett signaling strong confidence as the company holds a cash-heavy...
Applied Materials is set to report Q2 results after the close, as investors weigh demand signals for AI chips and adv...
Nvidia’s quarterly print arrives amid an AI demand cycle that remains uneven. Analysts say nvidia earnings don’t matt...
Investors are watching GameSquare closely as 2025 earnings unfold. This guide explains what to look for in the Q4 res...
AMD faces a high-stakes test as the AI buildout accelerates and competition intensifies. History warns advanced micro...
Redwire’s backlog and contract wins are lifting the stock, but the company remains unprofitable. This report weighs t...
Berkshire Hathaway's Greg Abel could be quietly steering a strategic tilt toward AI-enabled winners. This deep dive e...